What is the role of high-dose melphalan with autologous stem cell transplant (ASCT) in 2017?

 

In this week’s video, Dr. Brian Durie discusses the value of ASCT even with the use of newer drug regimens.

BOTTOM LINE:
We still value high-dose melphalan with ASCT in 2017.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org